M&A Deal Summary |
|
|---|---|
| Date | 2016-01-14 |
| Target | Laboratorios Brovel S.A. de C.V. |
| Sector | Life Science |
| Buyer(s) | Dechra Pharmaceuticals |
| Deal Type | Add-on Acquisition |
| Deal Value | 4M GBP |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1997 |
| Sector | Life Science |
| Revenue | 682M GBP (2022) |
Dechra Pharmaceuticals is an international specialist in veterinary pharmaceuticals and related products business. Its expertise is in the development, manufacturing, sales, and marketing of quality products exclusively for veterinarians worldwide. The company's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. Dechra Pharmaceuticals was founded in 1997 and is based in Northwich, United Kingdom.
| DEAL STATS | # |
|---|---|
| Overall | 10 of 16 |
| Sector: Life Science | 9 of 14 |
| Type: Add-on Acquisition | 8 of 14 |
| Country: Mexico | 1 of 1 |
| Year: 2016 | 1 of 3 |
| Size (of disclosed) | 9 of 12 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-08-03 |
GENERA d.d.
Rakov Potok, Croatia Genera is the oldest and largest manufacturer of animal health products in the Republic of Croatia with a strong market share in its local market and neighbouring countries. It operates three main divisions: Animal Health, which represents the majority of revenue, Agrochemicals and Human Pharmaceuticals. Over the last few years, vaccines have become a key part of the Animal Health Division. Genera has invested significantly in building its poultry vaccines capabilities, including regulatory submissions in the EU and elsewhere. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2016-03-15 |
Putney
Portland, Maine, United States Putney, Inc. is a pharmaceutical company, providing high quality, cost-effective generic medicines for pets. Putney's reliable supply of affordable drug options empowers veterinarians, allowing them to provide the best possible medicine at the best possible price, and supports pet owners, helping them afford to comply with veterinary recommendations. |
Buy | $200M |
